Skip to content
107 av. Victor Hugo, Paris 16th11 rue Lacépède, Paris 5th
Menopause

Menopause hormone therapy (HRT): do you really need it?

By Dr Olivier Kadoch, obstetrician-gynaecologistReviewed on Next review: October 20276 min read

In brief

Menopausal hormone therapy (MHT, often called HRT) is not necessary for every woman: it is indicated when hot flushes and other symptoms affect quality of life, and sometimes to prevent osteoporosis in a woman at risk. It is the most effective treatment for hot flushes. When it is started before 60 or within 10 years of the menopause, with no contraindication and combining transdermal oestradiol with progesterone, its benefit-risk balance is most favourable; it is reviewed every year.

What is menopausal hormone therapy?

Menopausal hormone therapy (MHT, often called HRT for "hormone replacement therapy") partly makes up for the fall in hormones produced by the ovaries. It combines:

  • an oestrogen, which relieves symptoms; in France, this is most often oestradiol, the natural hormone, applied to the skin (gel or patch) or taken by mouth;
  • a progestogen, essential for women who still have their uterus, to protect the endometrium from the risk of cancer; natural progesterone or dydrogesterone are preferred.

A woman who no longer has a uterus (after hysterectomy) can take oestrogen alone. The risks related to hormone-sensitive cancers are discussed below; our gynaecological cancer care page covers the treatment of these cancers.

Does every menopausal woman need HRT?

No. Menopause is a natural stage of life, not a disease. Many women have mild symptoms and do not need hormones. Treatment is discussed in three situations:

  1. Troublesome hot flushes and night sweats, often with poor sleep, irritability and joint pain: this is the main indication. HRT is the most effective treatment for them.
  2. Prevention of osteoporosis in a woman in early menopause with a higher risk of fracture (low bone density, past fractures), especially if she also has symptoms. According to French guidelines, HRT reduces the risk of fracture by 20 to 40%.
  3. Premature ovarian insufficiency (menopause before 40): treatment is then generally advised until the usual age of menopause, to protect the bones and the cardiovascular system.

Vaginal dryness on its own is usually treated locally, without systemic HRT.

What are the benefits and risks of HRT?

AreaEffect of treatmentWhat changes the risk
Hot flushes, sleepClear improvement; the most effective treatmentDose adjusted to symptoms
BonesPrevents bone loss; fracture risk reduced by 20 to 40%The effect wears off within 2 to 5 years of stopping
Breast cancerSlightly increased risk, especially with combined oestrogen and progestogen and with longer useNatural progesterone or dydrogesterone: extra risk probably limited for use of less than 5 to 7 years
Endometrial cancerIncreased if oestrogen is given alone to a woman who has her uterusRemoved by adding a suitable progestogen
Deep vein thrombosis, pulmonary embolismRisk increased with oral oestrogenTransdermal oestradiol: lower risk than the oral route
Stroke, heart attackIschaemic stroke increased with the oral route; coronary risk not increased if started before 60 or within 10 yearsAge at start of treatment, risk factors, route of administration

Sources: CNGOF and GEMVi guidelines 2021, NAMS 2022 position statement. These risks are expressed in relative terms: for an individual woman, the absolute risk depends on her age and medical history.

HRT gel, patch or tablets: which should I choose?

The choice of form is not just about convenience: it affects the risks.

  • Transdermal oestradiol (gel applied to the skin, patch): it avoids the first pass through the liver. French guidelines favour it because, unlike the oral route, it does not increase the risk of deep vein thrombosis and pulmonary embolism. It is particularly suitable for women who are overweight or former smokers, or who have vascular risk factors.
  • Oral oestradiol: easy to use, it remains an option for women with no thromboembolic or cardiovascular risk factors.
  • Progestogen: micronised natural progesterone, taken in the evening, or dydrogesterone are preferred, continuously or for part of the month. A "sequential" regimen causes period-like bleeds; a "continuous" regimen aims for no bleeding.

The dose is adjusted to symptoms: the aim is the dose that brings relief, which is then reviewed. Doses and regimens are discussed at your appointment, according to your situation.

Who should not take HRT?

Main contraindications

  • current or past breast cancer;
  • endometrial cancer or another hormone-sensitive cancer;
  • unexplained genital bleeding, which must be investigated first;
  • a history of heart attack, stroke or coronary heart disease;
  • severe, progressive liver disease;
  • deep vein thrombosis or pulmonary embolism, or thrombophilia: the oral route is contraindicated; the transdermal route is discussed case by case with specialist advice.

How is HRT started and monitored?

Before starting

  • A discussion of your symptoms, expectations, and personal and family history (cancers, blood clots, cardiovascular disease).
  • A clinical examination with blood pressure, weight and breast examination.
  • Up-to-date screening: mammogram and smear test according to age; cholesterol and blood sugar depending on the situation; bone density scan if treatment is aimed at preventing osteoporosis.

No hormone blood test is needed to diagnose menopause in a woman over 45 who has had no periods for 12 months.

During treatment

  • An appointment at 3 to 6 months to check effectiveness and side effects (breast tenderness, bleeding), then once a year.
  • A yearly review of whether to continue: there is no fixed maximum duration, but the benefit-risk balance changes with age and length of use.
  • Any unexpected bleeding on treatment should be reported and investigated (see bleeding after menopause).

When stopping, a gradual reduction is often suggested; hot flushes may return in some women.

What are the alternatives to HRT?

Non-hormonal treatments, with or without medicines, reduce hot flushes, though less effectively than HRT. They are covered in our article hot flushes: what to do if you are wary of hormones.

For bone health: regular physical activity, enough calcium and vitamin D, stopping smoking, and specific osteoporosis treatments if bone density requires them.

When should I see a doctor urgently while on HRT?

On hormone therapy, see a doctor promptly if you have unexpected bleeding, a lump in a breast or nipple discharge. In France, call 15 or 112 (or your local emergency number) if you have:

  • pain, swelling and warmth in a calf (possible deep vein thrombosis);
  • sudden breathlessness or chest pain;
  • weakness or numbness on one side of the body, difficulty speaking, sudden vision problems (possible stroke).

Would you like a medical opinion?Appointments in Paris 16th or 5th, or by video consultation.

Book an appointment

Frequently asked questions

Does HRT make you gain weight?

Studies do not show weight gain caused by the treatment itself. The weight gain common at menopause is linked to age, reduced activity and a redistribution of body fat.

How long can you take HRT?

There is no fixed maximum duration. Whether to continue is reviewed every year according to symptoms, age, risk factors and the patient's wishes.

Are "bioidentical" hormones safer?

In France, treatment already uses oestradiol and natural progesterone, identical to the hormones made by the ovaries. Unregulated compounded preparations have not been shown to be safer.

Can you start HRT after 60?

It is possible, but the benefit-risk balance is less favourable when treatment starts after 60 or more than 10 years after menopause, because of a higher cardiovascular and blood clot risk. The decision is made individually.

References

  • Gosset A, et al. — [Menopause hormone treatment in practice. Postmenopausal women management: CNGOF and GEMVi clinical practice guidelines]. Gynecol Obstet Fertil Senol, 2021 — doi:10.1016/j.gofs.2021.03.019 — PMID 33757922
  • Pouillès JM, et al. — [Menopause, menopause hormone therapy and osteoporosis. Postmenopausal women management: CNGOF and GEMVi clinical practice guidelines]. Gynecol Obstet Fertil Senol, 2021 — doi:10.1016/j.gofs.2021.03.015 — PMID 33753297
  • The North American Menopause Society — The 2022 hormone therapy position statement of The North American Menopause Society. Menopause, 2022 — doi:10.1097/GME.0000000000002028 — PMID 35797481

Dr Olivier KadochObstetrician-gynaecologist and gynaecological surgeon in Paris, seeing patients in Paris 16th and at the Centre de la Femme Paris 5. Former chef de clinique-assistant (senior registrar) at the Paris public hospitals (AP-HP); individually accredited by the French National Authority for Health (HAS). RPPS 10003957809. Background and practice locations

A question about your situation?Appointments at the practice or by video consultation, usually within one week to 10 days.

Book an appointment

General information article: it does not replace a medical consultation. In an emergency, call 15 or 112 in France, or your local emergency number.